The early movers could point to a disappointing meeting.
Key catalysts approach for Orphazyme, Gemini and Immutep.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.
Tocagen could soar or sink on interim brain cancer data, while judgement day approaches for Syndax.